“As the Menarini Group we are proud to have undertaken this path of commitment in the research and development of drugs in the oncology-hematology field. Today we are here to share the recent approval by the Italian Medicines Agency of a new first in class molecule for the treatment of multiple myeloma: selinexor, a selective oral inhibitor of the Xpo1 protein, which has received approval for two indications: one in the early lines of treatment, in association with dexamethasone and bortezomib, in relapsed patients who have already received therapy in previously, and one in penta-refractory patients in association with dexamethasone alone”. These are the words of Nicola Bencini, General Manager of Menarini Stemline Italia, at the press conference dedicated to new therapeutic perspectives for blood cancers held in Milan.
Alongside the news relating to Aifa’s green light for the reimbursement of selinexor in association with dexamethasone and bortezomib in relapsed multiple myeloma, there is that which concerns the first specific therapy for blastic plasmacytoid dendritic cell neoplasia. This is tagraxofusp, which in real life clinical practice has demonstrated an efficacy even higher than that detected during clinical studies. “Tagraxofusp is a Cd123 inhibitor – continues Bencini – which received approval last year for patients suffering from blastic plasmacytoid dendritic cell neoplasm, an orphan and lethal disease, which requires a multidisciplinary approach. Tagraxofusp represents in in this sense an additional therapeutic innovation for patients, in an attempt to be brought back to a transplant condition”.
“All this was made possible thanks to a close collaboration with the excellence of Italian hematology – concludes Bencini – with the academy and the university. The next steps will certainly go in this direction, trying to bring as much innovation as possible to patients suffering from blood cancers”.
